scholarly journals Changes in body mass index in boys with central precocious puberty over 2 years of gonadotropin-releasing hormone agonist therapy

2020 ◽  
Vol 25 (3) ◽  
pp. 169-173
Author(s):  
Kyung In Lim ◽  
Hae Sang Lee ◽  
Jin Soon Hwang
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Agonist Therapy ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

One-year treatment with gonadotropin-releasing hormone analogues does not affect body mass index, insulin sensitivity or lipid profile in girls with central precocious puberty

2019 ◽  
Vol 32 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Andrea J. Arcari ◽  
Analía V. Freire ◽  
María E. Escobar ◽  
María G. Ballerini ◽  
María G. Ropelato ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Insulin Sensitivity ◽  
Lipid Profile ◽  
Body Mass ◽  
Precocious Puberty ◽  
Central Precocious Puberty ◽  
Gonadotropin Releasing Hormone ◽  
Whole Body ◽  
Releasing Hormone ◽  
Prospective Longitudinal

Abstract Background Puberty is associated with a physiological decline in insulin sensitivity (IS). Overweight (OW) and obesity (OB) are common among girls with central precocious puberty (CPP). CPP is considered a risk factor for metabolic diseases. The aim of this study was to assess surrogate measures of IS, body mass index (BMI) and other metabolic parameters in CPP girls at diagnosis and during treatment with gonadotropin-releasing hormone analogues (GnRHa). Methods We present a prospective longitudinal study of CPP girls. The standard oral glucose tolerance test, homeostatic model assessment of insulin resistance (HOMA-IR), whole-body IS index (ISI) and fasting lipid profiles were evaluated at diagnosis, and at 6 and 12 months of treatment. Results Nineteen CPP girls were included; 17 were evaluable. At baseline, seven patients had normal weight (NW), five were OW and five were OB. During GnRHa treatment no significant changes were observed in BMI, HOMA-IR or ISI when considering the whole group. Whereas, when we analyzed patients according to BMI status, in NW patients, BMI increased significantly with no changes in HOMA-IR or ISI along treatment. In the OW/OB group, no significant differences were observed in BMI, HOMA-IR or ISI. Conclusions Girls with CPP showed a high frequency of OW/OB and a high prevalence of IR. GnRHa did not affect BMI, IS or the lipid profile when considering the whole cohort of patients. However, there was an increase in BMI in NW girls but not in OW/OB patients.

Sign in / Sign up

Export Citation Format

Share Document